Early Warning and Classification Model for Acute Non-traumatic Chest Pain

NCT ID: NCT06196307

Last Updated: 2024-01-09

Basic Information

• Recruitment Status: RECRUITING
• Total Enrollment: 188 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2022-08-30
• Study Completion Date: 2025-01-30

Brief Summary

Acute non-traumatic chest pain is one of the common causes of presentation in emergency patients, but the causes of acute non-traumatic chest pain are complex, the severity of the condition varies greatly, and the specificity of symptoms is not high. Machine learning and intelligent auxiliary models can greatly shorten the time of clinical decision-making, and improve the accuracy of etiological diagnosis in patients with chest pain, reduce the rate of misdiagnosis and missed diagnosis, and provide a clear direction for further treatment.

Detailed Description

Prospective observational studies used outpatient and follow-up information to construct an auxiliary early warning model of acute non-traumatic chest pain based on federated learning, and optimized the accuracy of early warning models through retrospective and prospective studies of large cohort data, and established an efficient and stable early warning and classification model for acute non-traumatic chest pain.

Conditions

Chest Pain

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

No cardiovascular adverse events (MACE) occurred during the 1-month period

No cardiovascular adverse events (MACE)，which include all-cause death, myocardial infarction, emergency revascularization, cardiogenic shock, cardiac arrest/ventricular fibrillation, stroke, and so on. Follow-up visits are conducted by in-person or telephone and registration is carried out.

Clinical evaluation, laboratory and cardiac imaging results, medication, surgery, and any hospitalization

Intervention Type: COMBINATION_PRODUCT

Examination： Electrocardiogram、 imaging examination、 X-ray, CTA, bedside echocardiography.

History of cardiovascular and pulmonary vascular drug therapy: Antithrombotic therapy (type, measurement) , Anticoagulation therapy (type, metering), Other drug treatments (type, measurement)

Group of cardiovascular adverse events (MACE) occurring during 1 month

Cardiovascular adverse events occur, the rest of the same as in the previous group

Clinical evaluation, laboratory and cardiac imaging results, medication, surgery, and any hospitalization

Intervention Type: COMBINATION_PRODUCT

Examination： Electrocardiogram、 imaging examination、 X-ray, CTA, bedside echocardiography.

History of cardiovascular and pulmonary vascular drug therapy: Antithrombotic therapy (type, measurement) , Anticoagulation therapy (type, metering), Other drug treatments (type, measurement)

Interventions

Clinical evaluation, laboratory and cardiac imaging results, medication, surgery, and any hospitalization

Examination： Electrocardiogram、 imaging examination、 X-ray, CTA, bedside echocardiography.

History of cardiovascular and pulmonary vascular drug therapy: Antithrombotic therapy (type, measurement) , Anticoagulation therapy (type, metering), Other drug treatments (type, measurement)

Intervention Type: COMBINATION_PRODUCT

Eligibility Criteria

Inclusion Criteria

1. older than 18 years old;

2. provided written informed consent;

3. Outpatient visits in the pilot hospitals from June 2022 to December 2022

Exclusion Criteria

1. did not provide written informed consent and were unwilling to be followed up;

2. traumatic chest pain;

3. systemic pain caused by malignant tumors or rheumatic diseases involving the chest;

4. transferred patients;

5. sudden death or death during hospital treatment;

6. women who are known to be pregnant or lactating;

7. have participated in other clinical trials within 3 months before enrolling in this trial or are currently participating in other clinical trials The lender;

8. According to the investigator's judgment, the patient was unable to complete the study or comply with the requirements of the study;

9. Patients were lost to follow-up.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Xiao-nan He

OTHER

Sponsor Role: lead

Responsible Party

Xiao-nan He

Chief physician of Emergency and Critical Care Center of Beijing Anzhen Hospital

Responsibility Role: SPONSOR_INVESTIGATOR

Locations

Xiaonan He

Beijing, Chaoyang, China

Site Status: RECRUITING

Countries

China

Central Contacts

Xiaonan He, Professor

Role: CONTACT

hxndoctor@126.com

15001108399

Haotian Wu, Bachelor

Role: CONTACT

wuhaotian3702@163.com

13966123702

Facility Contacts

Xiaonan HE, Professor

Role: primary

hxndoctor@126.com

15001108399

Other Identifiers

F0213-62272327

Identifier Type: -

Identifier Source: org_study_id